European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment
Journal of the European Academy of Dermatology and Venereology · 2025-05 · 39 (5) · 899-941
DOI: 10.1111/jdv.20472 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 19.12.2024. Verfasst von C C Zouboulis und 36 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Dermatology, Venereology, Allergology and Immunology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane and Fac…. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa. Die Arbeit wurde bisher 174-mal zitiert (Crossref) und nennt 279 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Hidradenitis Suppurativa Foundation e.V., European Reference Network for Rare and Complex Skin Diseases - Working group ALLOCATE.
Abstract (Originalsprache)
Introduction
This second part of the S2k guidelines is an update of the 2015 S1 European guidelines.
Objective
These guidelines aim to provide an accepted decision aid for the selection, implementation and assessment of appropriate and sufficient therapy for patients with hidradenitis suppurativa/acne inversa (HS).
Methods
The chapters have been selected after a Delphi procedure among the experts/authors. Certain passages have been adopted without changes from the previous version. Potential treatment complications are not included, being beyond the scope of these guidelines.
Results
Since the S1 guidelines publication, validation of new therapeutic approaches has almost completely overhauled the knowledge in the field of HS treatment. Inflammatory nodules/abscesses/draining tunnels are the primary lesions, which enable the classification of the disease severity by new validated tools. In relation to the degree of detectable inflammation, HS is classified into the inflammatory and the predominantly non‐inflammatory forms. While the intensity of the inflammatory form can be subdivided by the IHS4 classification in mild, moderate and severe HS and is treated by medication accordingly, the decision on surgical treatment of the predominantly non‐inflammatory form is based on the Hurley stage of the affected localization. The effectiveness of oral tetracyclines as an alternative to the oral combination of clindamycin/rifampicin should be noted. The duration of systemic antibiotic therapy can be shortened by a 5‐day intravenous clindamycin treatment. Adalimumab, secukinumab and bimekizumab subcutaneous administration has been approved by the EMA for the treatment of moderate‐to‐severe HS. Various surgical procedures are available for the predominantly non‐inflammatory form of the disease. The combination of a medical therapy to reduce inflammation with a surgical procedure to remove irreversible tissue damage is currently considered a holistic therapeutic approach.
Conclusions
Suitable therapeutic options while considering HS severity in the therapeutic algorithm according to standardized criteria are aimed at ensuring a proper therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Departments of Dermatology, Venereology, Allergology and Immunology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau, Germany.
- European Hidradenitis Suppurativa Foundation e.V., Dessau, Germany.
- Department of Dermatology, Venereology and Allergology, International Centre for Hidradenitis Suppurativa/Acne Inversa (ICH), Ruhr-University Bochum, Bochum, Germany.
- Dermatology Unit, Hôpitaux Unviversitaires de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
- HS Clinic, O.U. of Dermatology, Azienda Ospedaliera - University of Ferrara, Ferrara, Italy.
- University of Zagreb School of Medicine, Zagreb, Croatia.
ORCID-Profile: C C Zouboulis, F G Bechara, V Bettoli, M Dolenc-Voljč, E J Giamarellos-Bourboulis, Ø Grimstad, P Guillem, J R Ingram, D Ioannidis, A I Liakou, B M McGrath, A V Marzano, Ł Matusiak, A Molina-Leyva, F Prignano, D M L Saunte, J C Szepietowski, S Valiukevičienė, H H van der Zee, K R van Straalen, B Villumsen, G B E Jemec
Förderung
- European Hidradenitis Suppurativa Foundation e.V.
- European Reference Network for Rare and Complex Skin Diseases - Working group ALLOCATE
Zitieren
APA
Zouboulis, C. C., Bechara, F. G., Benhadou, F., Bettoli, V., Bukvić Mokos, Z., Del Marmol, V., Dolenc-Voljč, M., Giamarellos-Bourboulis, E. J., Grimstad, Ø., Guillem, P., Horváth, B., Hunger, R. E., Ingram, J. R., Ioannidis, D., Just, E., Kemény, L., Kirby, B., Liakou, A. I., McGrath, B. M., …, & Jemec, G. B. E. (2025). European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment. Journal of the European Academy of Dermatology and Venereology, 39(5), 899-941. https://doi.org/10.1111/jdv.20472
Vancouver
Zouboulis CC, Bechara FG, Benhadou F, Bettoli V, Bukvić Mokos Z, Del Marmol V, et al. European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment. Journal of the European Academy of Dermatology and Venereology. 2025;39(5):899-941. doi:10.1111/jdv.20472
BibTeX
@article{Zouboulis2025,
author = {Zouboulis, C C and Bechara, F G and Benhadou, F and Bettoli, V and Bukvić Mokos, Z and Del Marmol, V and Dolenc-Voljč, M and Giamarellos-Bourboulis, E J and Grimstad, Ø and Guillem, P and Horváth, B and Hunger, R E and Ingram, J R and Ioannidis, D and Just, E and Kemény, L and Kirby, B and Liakou, A I and McGrath, B M and Marzano, A V and Matusiak, Ł and Molina-Leyva, A and Nassif, A and Podda, M and Prens, E P and Prignano, F and Raynal, H and Romanelli, M and Saunte, D M L and Szegedi, A and Szepietowski, J C and Tzellos, T and Valiukevičienė, S and van der Zee, H H and van Straalen, K R and Villumsen, B and Jemec, G B E},
title = {European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2025},
volume = {39},
number = {5},
pages = {899--941},
doi = {10.1111/jdv.20472}
}
EUVIMED